Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Screening for Diabetes: When is it meaningful and how should it be performed
Prof. Lars Rydén
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
Prof. Richard Hobbs, MD
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
Prof. Eduard Montanya Barcelona
- CDMC 2018: Shifting gears in the management of diabetes and CVDLecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?
Prof John E Deanfield
